Results 171 to 180 of about 11,582,729 (334)

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images

, 2010
Nelleke Tolboom, Wiesje M. van der Flier, Jolanda Boverhoff, Maqsood Yaqub, Mike P. Wattjes, Pieter G. Raijmakers, Frederik Barkhof, Philip Scheltens, K. Herholz, Adriaan A. Lammertsma, B.N.M. van Berckel   +10 more
openalex   +2 more sources

Quantitative calibration of Tb-161 SPECT/CT in view of personalised dosimetry assessment studies

EJNMMI Physics
Background Terbium-161 (161Tb)-based radionuclide therapy poses an alternative to current Lutetium-177 (177Lu) approaches with the additional benefit of secondary Auger and conversion electron emissions capable of delivering high doses of localised ...
Lachlan McIntosh, Price Jackson, Brittany Emmerson, James P. Buteau, Ramin Alipour, Grace Kong, Michael S. Hofman   +6 more
doaj   +1 more source

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis

Molecular Oncology, EarlyView.
This study highlights the potential of automated enumeration using the ACCEPT software to refine circulating tumor cell (CTC) detection in metastatic colorectal cancer (mCRC). The automated method demonstrates improved accuracy and reduced variability compared to the manual approach.
Michela De Meo, Marco Siringo, Alessandro Vici, Ann Zeuner, Orietta Gandini, Paola Gazzaniga, Chiara Nicolazzo   +6 more
wiley   +1 more source

Molecular Basis of Mannose Recognition by Pradimicins and their Application to Microbial Cell Surface Imaging [PDF]

, 2019
Yu Nakagawa, Takashi Doi, K. Takegoshi, Takahiro Sugahara, Dai Akase, Misako Aida, Kazue Tsuzuki, Yasunori Watanabe, Tomohiko Tomura, Makoto Ojika, Yasuhiro Igarashi, Daisuke Hashizume, Yukishige Ito   +12 more
openalex   +1 more source

Fast mass spectrometry imaging for immunohistochemistry [PDF]

BIO Web of Conferences
Shamraeva Mariya, Sandström Edith, Garcia Kimberly G., Heeren Ron M. A., Anthony Ian G. M., van Nuffel Sebastiaan   +5 more
doaj   +1 more source

Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer

Cancer Imaging
Background Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is becoming standard of care for men with biochemical recurrence (BCR) of prostate cancer.
Sara Harsini, Patrick Martineau, Sonia Plaha, Heather Saprunoff, Catherine Chen, Julia Bishop, Scott Tyldesley, Don Wilson, François Bénard   +8 more
doaj   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Ex13R51 GluR2-5 from Synaptic molecular imaging in spared and deprived columns of mouse barrel cortex with array tomography.

, 2014
Nicholas Collins Weiler, Forrest Collman, Joshua T Vogelstein, Randal Burns, Stephen J Smith   +4 more
openalex   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source